Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic beta-interferon therapy for recurrent gliomas: a brief report.

M S Mahaley1, E J Dropcho, L Bertsch

  • 1Division of Neurological Surgery, University of Alabama, Birmingham.

Journal of Neurosurgery
|November 1, 1989
PubMed
Summary

Recombinant beta-interferon showed no response in recurrent glioma patients. However, three patients experienced tumor volume stabilization for up to 26 weeks, while four showed immediate disease progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus.

Journal of translational genetics and genomics·2022
Same author

KLF6 depletion promotes NF-κB signaling in glioblastoma.

Oncogene·2017
Same author

γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.

Gene therapy·2015
Same author

γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.

Gene therapy·2014
Same author

Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.

Gene therapy·2014
Same author

Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1.

Gene therapy·2011

Area of Science:

  • Neuro-oncology
  • Immunotherapy
  • Recombinant protein therapy

Background:

  • Recurrent gliomas are aggressive brain tumors with limited treatment options.
  • Interferons have immunomodulatory and antiproliferative effects.
  • Evaluating novel therapeutic strategies for recurrent gliomas is crucial.

Purpose of the Study:

  • To assess the efficacy of escalating dosages of recombinant beta-interferon in patients with recurrent gliomas.
  • To evaluate treatment response using neurological examination and computerized tomography (CT).

Main Methods:

  • Seven patients with recurrent gliomas received intravenous recombinant beta-interferon three times weekly.
  • Dosages were escalated during the treatment course.
  • Tumor response was monitored via neurological assessments and contrast-enhanced CT scans.

Related Experiment Videos

Main Results:

  • No objective response was observed in any patient based on neurological examination or CT findings.
  • Tumor volume stabilization was noted in three out of seven patients for 8 to 26 weeks.
  • Four patients experienced immediate disease progression despite treatment.

Conclusions:

  • Recombinant beta-interferon, at the dosages tested, did not demonstrate significant efficacy in treating recurrent gliomas.
  • A subset of patients may experience temporary tumor stabilization, warranting further investigation.
  • The limited benefit suggests that recombinant beta-interferon may not be a suitable treatment for most recurrent glioma cases.